231 related articles for article (PubMed ID: 28012485)
1. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study.
Kim JS; Lee EJ; Chang DI; Park JH; Ahn SH; Cha JK; Heo JH; Sohn SI; Lee BC; Kim DE; Kim HY; Kim S; Kwon DY; Kim J; Seo WK; Lee J; Park SW; Koh SH; Kim JY; Choi-Kwon S;
Lancet Psychiatry; 2017 Jan; 4(1):33-41. PubMed ID: 28012485
[TBL] [Abstract][Full Text] [Related]
2. Depressive Symptoms in Stroke Patients: Are There Sex Differences?
Lee EJ; Kim JS; Chang DI; Park JH; Ahn SH; Cha JK; Heo JH; Sohn SI; Lee BC; Kim DE; Kim HY; Kim S; Kwon DY; Kim J; Seo WK; Lee J; Park SW; Koh SH; Kim JY; Choi-Kwon S
Cerebrovasc Dis; 2020; 49(1):19-25. PubMed ID: 32023608
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
Burke WJ; Gergel I; Bose A
J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
[TBL] [Abstract][Full Text] [Related]
4. Escitalopram continuation treatment prevents relapse of depressive episodes.
Rapaport MH; Bose A; Zheng H
J Clin Psychiatry; 2004 Jan; 65(1):44-9. PubMed ID: 14744167
[TBL] [Abstract][Full Text] [Related]
5. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Robinson RG; Jorge RE; Moser DJ; Acion L; Solodkin A; Small SL; Fonzetti P; Hegel M; Arndt S
JAMA; 2008 May; 299(20):2391-400. PubMed ID: 18505948
[TBL] [Abstract][Full Text] [Related]
6. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
[TBL] [Abstract][Full Text] [Related]
7. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
Lepola UM; Loft H; Reines EH
Int Clin Psychopharmacol; 2003 Jul; 18(4):211-7. PubMed ID: 12817155
[TBL] [Abstract][Full Text] [Related]
8. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial.
Kim JM; Bae KY; Stewart R; Jung BO; Kang HJ; Kim SW; Shin IS; Hong YJ; Kim JH; Shin HY; Kang G; Ahn Y; Kim JK; Jeong MH; Yoon JS
J Clin Psychiatry; 2015 Jan; 76(1):62-8. PubMed ID: 25375836
[TBL] [Abstract][Full Text] [Related]
9. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM; Llorca PM; Despiegel N; Verpillat P
Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
11. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
12. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
Ventura D; Armstrong EP; Skrepnek GH; Haim Erder M
Curr Med Res Opin; 2007 Feb; 23(2):245-50. PubMed ID: 17288677
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
Kornstein SG; Bose A; Li D; Saikali KG; Gandhi C
J Clin Psychiatry; 2006 Nov; 67(11):1767-75. PubMed ID: 17196058
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
15. Post-Stroke Depressive Symptoms: Varying Responses to Escitalopram by Individual Symptoms and Lesion Location.
Lee EJ; Kim JS; Chang DI; Park JH; Ahn SH; Cha JK; Heo JH; Sohn SI; Lee BC; Kim DE; Kim HY; Kim S; Kwon DY; Kim J; Seo WK; Lee J; Park SW; Koh SH; Kim JY; Choi-Kwon S; Kim MS; Lee JS
J Geriatr Psychiatry Neurol; 2021 Nov; 34(6):565-573. PubMed ID: 32912058
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.
Kim EY; Kim SH; Lee HJ; Lee NY; Kim HY; Park CHK; Ahn YM
J Affect Disord; 2019 Dec; 259():91-97. PubMed ID: 31445345
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial.
EFFECTS Trial Collaboration
Lancet Neurol; 2020 Aug; 19(8):661-669. PubMed ID: 32702335
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
Wade A; Michael Lemming O; Bang Hedegaard K
Int Clin Psychopharmacol; 2002 May; 17(3):95-102. PubMed ID: 11981349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
